WRLFMD Global update. Donald King

Transcription

1 WRLFMD Global update Donald King WRLFMD Team: Valerie Mioulet, Nick Knowles, Ginette Wisden, Bryony Armson, Pip Hamblin, Kasia Bachanek-Bankowska, Kelly Adams, Jemma Wadsworth, Begoña Valdazo-González, Britta Wood, Barsha Thapa, Bob Statham, Trish Ryder, Sarah Belgrave

2 Recent staff changes at WRLFMD Nigel Ferris Retirement ~35 years Geoff Hutchings Retirement 40 years Yanmin Li Head of Vaccine Research Boehringer-Ingelheim Shanghai, China 10 years Jef Hammond Director Elizabeth Macarthur Agricultural Institute Australia 5 years +

3 Role of WRLFMD Global surveillance Emergence of new viral lineages Patterns of virus movement Performance of vaccines EuFMD strategic objectives Preparation for a potential FMD outbreak Monitoring of risks Early warning Validation and testing of systems

4 Recent submissions to WRLFMD October 2012 date: 360 samples 199 Isolates Represent 5 FMDV serotypes: SAT 1 SAT 2 Asia 1 O A No serotype C since 2004

5 Global sampling Countries sending samples to WRLFMD October October 2013 PAT Bhutan Hong Kong SAR Clinical samples Sri Lanka Viral sequences Reports for these samples can be found at

6 Enhanced surveillance through the OIE/FAO FMD Laboratory Network WRLFMD: RRLSEA: LVRI: FGI ARRIAH: PDFMD: RRLSSA: FMD-Laboratory: PANAFTOSA: SENASA: ARC-OVI: PIADC: CODA-CERVA-VAR: Pirbright, UK Pakchong, Thailand Lanzhou, China Vladimir, Russia Mukteswar, India Gabarone, Botswana Embakasi, Kenya Rio de Janeiro, Brazil Argentina Onderstepoort, RSA Plum Island, USA Belgium Approximately 1800 samples tested during 2012 Report published on an annual basis Network meeting in Bangkok (12-14 th November)

7 Harmonisation of laboratory capabilities: Training and proficiency testing Annual training course for laboratory diagnostics Training course for vaccine matching WRLFMD mission to Balkan States FMD diagnostics training course April 2013 Annual proficiency testing scheme Aims to harmonise the performance of laboratory tests Important component of quality assurance schemes 2013 exercise (4 panels): 80 invited laboratories 46 shipments dispatched Vaccine matching training course Sept 2013

8 Conjectured Status of FMD Endemic Intermediate, sporadic Free with vaccination Countries with multiples zones: FMD-free, free with vaccination or not free Free. Virus present in game parks Free

9 : Changing patterns and threats SAT 2 North Africa Multiple East Asia Asia 1 The Middle East

10 Changing global patterns: SAT 2 in North Africa First FMD cases in Egypt due to serotype SAT 2 since 1950 Cases associated with high mortality ~50% particularly in young animals due to myocarditis Sequence data supported at least two introductions of SAT 2 FMDV into Egypt within the SAT 2 topotype VII Cameroon 2005 SAT2/LIB/40/ SAT2/LIB/41/2012 SAT2/LIB/39/2012 SAT2/SUD/1/2007 (GU566071) SAT2/NIG/2/ SAT2/NIG/5/2008 SAT2/NIG/6/ SAT2/NIG/7/ SAT2/NIG/4/2008 SAT2/NIG/1/ SAT2/NIG/2/2008 SAT2/NIG/3/2008 SAT2/NIG/8/ SAT2/LIB/1/2003 SAT2/LIB/7/2003 SAT2/NGR/15/2005 SAT2/SEN/27/2009 SAT2/EGY/2/2012 SAT2/SAU/6/2000 (AF367135) SAT2/CAR/P12/2000 (VDI 44/1)(HM211082) SAT2/ERI/12/98 (AF367126) 100 SAT2/ERI/1/98 (AY343933) 100 SAT2/ERI/4/98 (AY343934) SAT2/EGY/9/2012 SAT2/EGY/11/ SAT2/EGY/13/2012 SAT2/EGY/6/2012 SAT2/EGY/10/2012 SAT2/EGY/14/2012 SAT2/EGY/15/2012 SAT2/EGY/3/2012 SAT2/EGY/4/2012 SAT2/EGY/5/2012 Distinct from other contemporary SAT 2 lineages in the Middle East and North Africa topotype VII from Libya topotype IV from Bahrain

11 Changing global patterns: East and Central Asia FMD viruses from Southeast Asia are appearing in East and Central Asia O/SEA/Mya-98: Widespread; at least two introductions from SEA into China, Russia, Mongolia, North and South Korea, Japan Daniel Dalet / d-maps.com 1000 km A/ASIA/Sea-97: 600 mi Introduction from SEA into China and South Korea, Mongolia (west) and Kazakhstan (2013) O/ME-SA/PanAsia: Introduction from SEA into China and Kazakhstan (2010) What is driving these changing patterns? TCS: Full genome TAI/22/ MYA/5/ MAY/7/2007 CHN/Mya98/33-P BY/CHA/ RUS/Aug 2010 JPN/1/ HKN/15/ [98] 34 3 SKR/4/2010 GSLX/ GZ/CHA/2010 HKN/20/2010 MOG/C-10/ MOG/7/ DKR/31/2011 RUS/Jul 2010 SKR/5/ Knowles et al., 2012 Valdazo-Gonzalez et al., 2013

12 Monitoring vaccine matching A/ASIA/Sea-97 viruses from Southeast and East Asia Recent results: Field Viruses A/MOG/1/2013 A/MOG/5/2013 A/VIT/25/2012 A/VIT/26/2012 A/TAI/13/2012 A/TAI/16/2012 A/TAI/2/2013 A/TAI/5/2013 A/VIT/5/2013 A/VIT/6/2013 A/VIT/15/2012 A/VIT/16/2012 Vaccines A May97 A22 Irq A Iran 05 A Tur 06 borderline borderline Traffic lights Match No Match

13 (New) connections between The Middle East and East Asia Kazakhstan: FMD Threats (South East Asia) Kurchum Urdzhaz Spread of two different serotype O lineages and serotype A O/ME-SA/PanAsia Kazakhstan (2010) also reported in China A/ASIA/Sea-97 Kazakhstan (2013) also reported in China and South Korea O/SEA/Mya-98 a number of outbreaks in China (west), Russia, Mongolia, N&S. Korea, Japan

14 (New) connections between The Middle East and East Asia Kazakhstan: FMD Threats Spread of two different serotypes from South Asia/Middle East O/ME-SA/PanAsia-2 - in Kazakhstan ( ) A/ASIA/Iran-05 - in Kazakhstan (2012) also recent incursions into Russia (North Caucasus)

15 Changing global patterns: Spread of new antigenic variants in the Middle East Emergence of a new Asia 1 lineage (Sindh-08) with poor match Asia 1 Shamir (ISR/3/89) First recognised in Pakistan (2008) Natural immunity may be low in Middle East Lineage has now spread westward into Afghanistan, Iran, Turkey and Bahrain Spread mirrors recent transboundary movements of O/PanAsia and A/Iran-05 Can we predict when/where these events will occur? Differences (in red) between Asia 1 Shamir (ISR/3/89) and Asia 1 PAK/29/2009 (Sindh-08)

16 Sindh-08 lineage: Lack of protection of existing Asia 1 vaccines Field Viruses TUR 2/2013 TUR 13/2013 PAK 10/2012 PAK 29/2012 PAK 30/2012 PAK35/2012 PAK 37/2012 PAK 91/2011 PAK 5/2012 AFG 66/2011 AFG 78/2011 IRN 54/2011 IRN 10/2012 Vaccines Asia1 Shamir (normal payload) Asia1 Shamir (high payload) Asia 1 Ind 8/79 Match No Match

17 Working together: International FMD Vaccine Strategic Reserves Network Established in 2010 Important forum for antigen/vaccine banks stakeholders Exchange of information/new developments Harmonisiation of standards Pont of contact with vaccine manufacturers EU, QUAD countries, Mexico Annual Report 2013 Current Chair (from 1 st October) Dr Hernando Duque (APHIS, USA) Next meeting (teleconference) scheduled within the next 4 weeks Opportunities for increased coordination in other areas? Diagnostic reserve (commercial NSP/SP assays)

18 WRLFMD: The future Building infrastructure will be completed by Q Pirbright Institute Redevelopment: High Containment Laboratory (DP1)